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Abstract 
The risk of false positive results in noninvasive prenatal diagnosis focused on fetal gender 
and RhD status determination could be a problem in clinical routine. This is because these 
tests are based on detection of presence of DNA sequences with high population frequency 
and so there is the risk of sample contamination during sample collection and processing.  
In our study the different fragmentation of fetal and maternal DNA molecules present in 
maternal circulation was utilized in identification of contaminated samples. Amplification of Y-
chromosome specific assays different in size was tested on circulating DNA samples. 
Of the four tested assays two shorter (84 and 177 bp) showed expected qPCR efficiency and 
have comparable amplification profiles. The difference in Ct values between these two 
assays was found to be statistically significant in comparison of fetal male and normal male 
samples (p<0.0001) as well as in blinded pilot study performed on 10 artificially contaminated 
and 10 non-contaminated samples (F=34.4, p<0.0001) that were all identified correctly. 
Our results showed that differently sized assays performed well in detection of external 
contamination of samples in noninvasive prenatal fetal gender test and could be of help in 
clinical laboratories to minimize the risk of false positive results.  
 
Introduction 
The detection of cell-free fetal DNA in the maternal circulation during gestation was a 
milestone [1]. It has revolutionized the field of non-invasive prenatal diagnosis [2]. The 
original protocol for the detection of fetal DNA was based on the detection of the Y-
chromosomal sequences. Although several other approaches are known, this is still the gold 
standard for a simple detection and quantification of fetal DNA [3]. 
The main application for the circulating fetal DNA in maternal plasma is the use in the 
screening for the Down syndrome [4]. This possibility becomes available for many pregnant 
women with the spread of the high throughput sequencing technology. Even more, it is now 
possible, although still very costly, to sequence the whole fetal genome from DNA isolated 
from maternal plasma [5]. However, beyond these methods requiring sophisticated 
equipment, there are several simple PCR based analyses that can be done. 
RhD genotyping and fetal sex determination are among those that have already advanced 
into routine clinical and/or commercial use [6]. The accuracy of the particular analyses 
reaches 99% and more [7]. However, there is still space for improvement, especially in the 
determination of fetal sex. It is of commercial interest as many pregnant women want to 
know the gender of their baby very early just out of curiosity. In several countries this 
possibility has, of course, ethical aspects that have to be taken into account [8]. The 
possibility to detect fetal sex early during the first trimester is also of clinical value. It enables 
a very precise prognosis for the fetus of risk for X-chromosome linked genetic disorders [9]. 
The non-invasive fetal sex determination is based on a simple PCR targeting the male Y-
chromosomal sequences [10]. For the quantification of fetal DNA from a male fetus a single 
copy gene is used as a target, typically the SRY gene. However, multicopy sequences such 
as DYS14 are more suitable for qualitative assessments due to higher sensitivity of the PCR. 
Plasma DNA isolated from non-pregnant women and from pregnant women with a female 
fetus should not contain any Y-chromosomal sequences. A biological exception might be the 
vanishing twin syndrome [11]. Unfortunately, there is always a small but important risk of 
technical variability due to contamination during blood sampling and centrifugation, plasma 
DNA isolation or during the PCR setup. 
As there is no positive marker for the female sex, the absence of the Y-chromosomal 
sequences is interpreted as a predicted female fetus. A meta-analysis showed that fetal sex 
determination using cell-free fetal DNA has high sensitivity and specificity [12]. Nevertheless, 
even a low chance of error below 1% is of importance due to the use of this test for clinical 
decisions about the progress or discontinuation of pregnancies at sex-linked genetic risk. 
The test is prone to bias due to contamination with external male DNA. The SAFE 
collaborative project suggested multiple control mechanisms [13]. None of these widely 
accepted and followed suggestions is, however, able to distinguish contaminating external 
male DNA from fetal male DNA. 
Using simple PCR targeted at Y-chromosomal sequences of various lengths we tested if it is 
possible to detect contaminating external male DNA in DNA samples from maternal plasma. 
We make use of the main biological feature of fetal DNA – its fragmentation [14]. The size of 
the fragments of fetal DNA present in maternal plasma varies but is mostly about 146 bp – 
the length the DNA from one nucleosome [15]. Others have shown that the maximum 
fragment length of cell-free fetal DNA circulating in maternal plasma comprises of 2 
nucleosomes or less, but not exceeding 3 [16]. We suggest that the short length of fetal DNA 
fragments can be used not only for distinguishing fetal and maternal DNA [17], but also for 
distinguishing male fetal DNA and male contaminating (non-fetal) DNA. Quantitative real time 
PCR targeted at short and long Y-chromosomal sequences can detect male fetal DNA 
(positive only for short PCR targets) and male contaminating DNA (positive for both, short 
and long PCR fragments). In addition to this new technology based on novel PCR assays we 
suggest an algorithm for the use in a routine clinical laboratory focusing on not only in fetal 
sex determination. 
 
Materials and Methods 
Samples 
Samples of peripheral blood taken from 60 pregnant women bearing female and male 
fetuses (in 10th – 20th weeks of gestation) were collected after informed consent was 
acquired. Blood samples were stored at 4 – 8 ° C and processed within 24 h. The plasma 
was separated by centrifugation two times at 2200 g for 10 min, then aliquoted to 1000 μL 
and stored at – 20°C until further processing. Samples with lower than 1000 μL volume of 
plasma were pooled in a way that it was possible to prepare 40 different pooled samples 
represented by 10 samples of female and 30 samples of male fetal gender. The pooled 
samples were prepared from one to three individual samples. Additionally, whole blood 
samples of ten males were used as control male samples (non-fetal) in the study. 
 
DNA extraction 
Circulating DNA (cDNA) was extracted from 40 individual or pooled plasma samples with use 
of DSP Virus Kit (Qiagen, Hilden, Germany). In the standard vacuum extraction protocol one 
modification was done, as the volume of plasma sample that should be processed is in 
original protocol 500 μL and we have to start with 1000 μL the volumes of protease, lysis 
buffer and ethanol were doubled in the first part of the DNA extraction protocol and the lysis 
was performed in 5 mL eppendorf tubes (Eppendorf, Hamburg, Germany). The isolated 
circulating DNA was eluted in 100 μL of MBG water. In control male samples DNA was 
extracted from 200 μL of whole blood with use of standard protocol and DNA Blood Mini Kit 
(Qiagen, Hilden, Germany). 
 DNA sample utilization in the study 
Of the isolated DNA samples – 40 cDNA and 10 control male samples, 20 of cDNA and 10 of 
control male samples were used in the first phase to test the ability of assays in qPCR and in 
detection of difference in performance of different assays regarding to the length of their 
amplicons. In the second phase 10 of remaining 20 cDNA samples (5:5 of male:female 
bearing pregnancies) were contaminated with control male DNA, while the other 10 (5:5 of 
male:female bearing pregnancies) were not contaminated. Samples were blinded, analysed 
and the statistical analysis of results of qPCR was performed. 
 
Contamination of extracted DNA samples 
The concentration of male DNA used for contamination of isolated circulating DNA of 
pregnant women was determined with use of spectrophotometer and the DNA was diluted to 
the concentration of 50 pg/μL (~7.5 GEq/μL). Ten μL of the diluted contaminaning male DNA 
was added to the 65 μL of isolated circulating DNA of pregnant women. 
 
Quantitative PCR 
Isolated circulating DNA was quantified using real-time PCR with singleplex TaqMan probe 
assays. Four assays (one previously known, three novel assays) with lengths of amplicons 
between 84 bp and 290 bp targeted at DYS14 sequence were designed with use of online 
tool Primer3 [http://biotools.umassmed.edu/bioapps/primer3_www.cgi]. The four assays were 
based on combination of 4 primers and one common TaqMan probe with sequences and 
corresponding amplicon lengths summarized in Table 1 and Figure 1, respectively. 
 
Table1: Sequences of primers and probe used in amplification of four tested assays. 
Primer name Sequence 
DYS14-F 5´-GGGCCAATGTTGTATCCTTCTC-3´ [10] 
DYS14-R 5´-GCCCATCGGTCACTTACACTTC-3´ [10] 
DYS14-F_long 5´-GTTAATGCCCAAGCCAGGA-3´ 
DYS14-R_long 5´-CAATAGTACCCACGCCTGCT-3´ 
DYS14-probe 5´- TCTAGTGGAGAGGTGCTC -3´ [10] 
 
 
Figure1: Scheme of four DYS14 targeted amplicons tested in the study with their corresponding sizes. 
 
PCR amplification was performed according to our previously published study [18]. Briefly, 5 
μL of template DNA was used in 15 μL reaction volume containing final concentrations of 1 × 
QuantiFast Probe PCR Kit (Qiagen, Hilden, Germany), 1 μmol/L of each primer and 0.8 
μmol/L of TaqMan probe. The following PCR program was used: initial denaturation step at 
95 ° C for 3 min, followed by 50 cycles each consisting of denaturation step at 95 ° C for 3 s 
and combined annealing/extension step at 60 ° C for 30 s. QPCR reactions run in the first 
phase in duplicates and in the second phase in triplicates. The real-time PCR was performed 
on Eppendorf Mastercycler ep realplex 4S (Eppendorf, Hamburg, Germany) and Roche 
LightCycler 480 (Roche, Rotkreuz, Switzerland) instruments with their corresponding 
softwares. The Ct value of 38 was set as the cuttof for positive signal of amplification. 
 
Statistical analysis 
Data were analyzed using Microsoft Excel 2007, GraphPadPrism® version 5.03 and IBM 
SPSS 21. Blinded data were clustered using the K-Means clustering routine. Differences 
between grouped Ct values for the assay with the longer amplicon (177 bp) and the shortest 
amplicon (84 bp) were analyzed using One-way ANOVA with Bonferroni corrected post hoc 
t-test. 
 
Results 
Assays performance and fetal DNA amplification vs. control male DNA amplification 
differencies 
All 4 tested assays were found to be suitable to amplify their genomic targets with 
comparable qPCR efficiency (100.29% - 105.58%). When qPCR curve profiles were 
compared assays with shorter amplicons (84 bp and 177 bp) gave different profiles in 
comparison to the assays with longer amplicons (194 bp and 290 bp) (Figure 2). This was 
the reason that only the two shorter assays (84 bp and 177 bp) were used in subsequent 
analyses. 
  
Figure 2: The comparison of amplification of DNA sample of pregnant woman bearing male fetus (A) 
and control male DNA (B) with all four tested assays represented with qPCR curve profiles reactions 
run in duplicates). Among shorter assays the 84 bp assay is the first from the left and the 177 bp 
assay the second from the left.  
The difference in performance of the two tested assays with 84 bp and 177 bp amplicons 
between cDNA containing and control male DNA containing samples was recorded as the 
shift of Ct value in cDNA samples, while it was not present in control male DNA samples. In 
analysis of 20 cDNA samples of women bearing male fetuses and 10 control male DNA 
samples the difference measured as difference between Ct values of 177 bp and 84 bp 
assays was found to be statistically significant (p<0.0001, Figure 3). 
 
Figure 3: Differences between Ct values of 177 bp and 84 bp assays calculated for fetal and control 
male DNA samples (*** - p<0.0001).   
Analysis of contaminated vs. non-contaminated samples  
The cluster analysis of blinded artificially contaminated samples correctly identified all 
contaminated samples as well as differentiated non-contaminated samples of pregnant 
women bearing male and female fetuses (F=34.4, p<0.0001, Figure 4).  
 
Figure 4: Group analysis and subsequent ANOVA analysis of contaminated and non-contaminated 
samples presented as differencies between Ct values of 177 bp and 84 bp assays (A - contaminated 
samples, B - non-contaminated samples of pregnant women bearing male fetuses, C - non-
contaminated samples of pregnant women bearing female fetuses). 
 
Discussion 
Although noninvasive prenatal gender testing made huge steps forward from the discovery of 
the presence of fetal DNA in maternal circulation in 1997, there were historically at least two 
issues which were needed to be solved before this test could be presented as truly clinical 
diagnostic test. These two issues were determination of presence of fetal DNA in analyzed 
sample in relevant amount (exclusion of false negatives) and detection of contamination by 
external male DNA during the sample processing (exclusion of false positives). The 
determination of presence of fetal DNA in relevant amount, which is sufficient for fetal gender 
testing, was recently successfully solved with the combination of utilization of differential 
methylation-based assay used previously known target RASSF1A with ultrasensitive method 
based on pyrophosphorolysis-activated polymerization [19]. In our study the novel approach 
based on known characteristics of fetal DNA in maternal circulation, the high level of 
fragmentation, was used in testing of possibility to detect contaminating male DNA. Usually 
in laboratories where non-invasive prenatal fetal gender tests are performed only females are 
working to minimize the possibility of test contamination with external male DNA. Such 
laboratory strategy is easily applicable to many laboratories, but the problem could arise 
when different than noninvasive prenatal fetal gender test should be performed, e.g. 
noninvasive prenatal RhD test. As could be expected the contaminating external male DNA 
should differ from fetal DNA gained from maternal plasma in level of fragmentation. The 
external male DNA should be less fragmented than the fetal DNA, therefore qPCR assays 
targeted on the same chromosomal region but producing amplicons with specifically different 
sizes could be used for differentiation of contaminated and non-contaminated samples. To 
test this we utilize one known and designed 3 novel assays with amplicon sizes reaching 84 
bp, 177 bp, 194 bp and 290 bp, all targeted to DYS14 sequence. The assay with shortest 
amplicon (84 bp) was firstly described in 2005 [10] and afterward used in many laboratories 
for prenatal fetal gender determination. The other two assays (177 bp and 194 bp) were 
designed to be larger than the peak of cell free fetal DNA isolated from maternal plasma – 
146 bp [15] and the last assay with largest amplicon (290 bp) should be close to the maximal 
DNA fragment size of cell free fetal DNA [16, 20]. In concordance with this knowledge we 
were able to get amplification from all four assays in cell free fetal DNA containing samples. 
All four assays performed well on control male DNA samples were these reached similar 
qPCR amplification efficiencies. In the first phase of the study, when only control male DNA 
and cDNA of pregnant women with male fetuses were analyzed, the expected shift in Ct 
values between shortest assay (84 bp amplicon) and all of the larger assays (177 bp, 194 bp 
and 290 bp amplicons) was recorded in cDNA samples, while it was not present in control 
male DNA samples (the lowest tested DNA amount in control male DNA samples was 5 
genomic equivalents in qPCR reaction). But as the two shorter assays (84 bp and 177 bp) 
and two larger assays (194 bp and 290 bp) differ when amplification curves were compared 
and in some cell free fetal DNA samples the amplification in larger assays (194 bp and 290 
bp) was not detected we decided not to continue with the larger assays in the second phase 
of the study as well to perform statistical analysis only for the two shorter assays (84 bp and 
177 bp). The shift in Ct values was quantified as the difference of Ct value recorded for the 
larger assay (177 bp) and Ct value recorded for the shortest assay (84 bp). Statistical 
analysis with use of t-test reveals that the Ct difference between the tested groups was 
statistically significant (p<0.0001). With the calculated average shift (2.79, SD=±0.79) it was 
possible to estimate the proportion of DNA targets amplifiable with the shortest (84 bp) and 
the longer (177 bp) assay. There was on average 8-times (8.03, SD=±4.62) more DNA 
targets which were amplified by the shortest assay, what is in concordance with previous 
findings, where the proportion of cffDNA fragments in maternal plasma >193 bp was 20 % 
[17]. In the second phase of the project half (10) of the tested samples was artificially 
contaminated with control male DNA and blinded. The proportion of contaminating control 
male DNA to cffDNA was approx. 1:1 in terms of GEq in DNA solution used in qPCR 
amplification. In both groups of samples (contaminated and non-contaminated) half of the 
samples (5:5) were DNA from male bearing pregnancies and half from female fetus bearing 
pregnancies. After cluster analysis of Ct differences between the longer (177 bp) and the 
shorter (84 bp) assay three groups of samples were correctly identified, with group 1 
containing 10 samples, which were artificially contaminated, and groups 2 and 3 (both with 5 
samples) which contained non-contaminated samples from male and female fetus bearing 
pregnancies, respectively. ANOVA analysis performed after cluster analysis with the 
identified Ct differences in the three groups confirmed the results of the first phase.  
 
Conclusion 
Our study reveals the possibility to detect external contamination by male DNA in 
noninvasive prenatal fetal gender test with assays amplifying amplicons with different but 
specific sizes in qPCR. We designed simple, fast and cheap algorithm, which uses same 
target sequence for detection of true positive and false positive samples. For the detection of 
contamination the difference between Ct values of longer assay (177 bp) and shorter assay 
(84 bp) led to statistically significant results and clear differentiation of fetal and non-fetal 
male DNA samples. Moreover, the identified algorithm was successfully utilized in analysis of 
blinded cell-free fetal DNA containing samples which were artificially contaminated with 
external male DNA and correct clustering of all groups of samples was recorded. In the 
future our algorithm should be tested on different targets, e.g. RhD, what could confirm its 
universal applicability in assays used in noninvasive prenatal testing. This could lead to 
minimizing the proportion of inconclusive results, when external contamination could be the 
problem. 
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